Clinical Trial Update: Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Relmacabtagene autoleucel in combination with sintilimab for relapsed/refractory B-cell lymphomas; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Relmacabtagene Autoleucel (relmacabtagene autoleucel)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL) | Phase 2 | Status: RECRUITING